This is the authors' abstract. We don't add key points for this paper.
Despite the growing evidence of improved patient outcomes and of a substantially reduced environmental impact of propofol-based total intravenous anesthesia when compared to volatile-based techniques, the vast majority of general anesthetics still use volatile agents for the maintenance phase. A significant reason for this is the lack of suitable point-of-care, real-time blood propofol measurement techniques. Here we present an enzyme-based electrochemical biosensor for the detection of propofol. Deactivated yeast cells expressing the enzyme cytochrome P450 2B6 are immobilized, alongside gold nanoparticles, within a chitosan film upon the surface of a screen printed electrode. In the presence of the cofactor NADPH, the enzyme converts propofol to a quinone/quinol redox pair that can be detected using simple electrochemistry. This approach avoids the issue of electrode fouling that commonly renders electrochemical propofol sensors impractical. The sensor has a limit of detection of 67 ± 7 ng/ml and a sensitivity of 4.2 ± 0.2 nA/μ g/ml/mm². It has been successfully demonstrated in a serum-like solution and has shown a linear response across the therapeutic range of propofol (1 –10~μ g/ml). Additionally, the sensor has shown good specificity with regards to potential interfering compounds.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ferrier et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: